Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 21:15:1387404.
doi: 10.3389/fneur.2024.1387404. eCollection 2024.

Clarifying the association between Parkinson's disease and vitiligo: a population-based large-scale study

Affiliations

Clarifying the association between Parkinson's disease and vitiligo: a population-based large-scale study

Khalaf Kridin et al. Front Neurol. .

Abstract

Objective: Our knowledge about the association between vitiligo and Parkinson's disease (PD) is sparse. We sought to investigate the bidirectional epidemiological association between vitiligo and PD.

Methods: A population-based study was conducted using Clalit Health Services (CHS) database (2002-2019) using both a cohort study and a case-control study design. Adjusted hazard ratio (HR) and odds ratio (OR) were calculated by multivariate Cox and logistic regressions, respectively.

Results: Overall, 20,851 vitiligo patients and 102,475 controls were included. The incidence of new-onset PD was 2.9 (95% CI, 2.1-4.1) and 4.3 (95% CI, 3.8-4.9) cases per 10,000 person-years among patients with vitiligo and controls, respectively. Patients with vitiligo had a significantly decreased risk of developing new-onset PD [adjusted HR, 0.62; 95% confidence interval (CI), 0.43-0.89, p = 0.009]. On the other hand, the likelihood of having vitiligo after a preexisting diagnosis of PD was not statistically different (adjusted OR, 0.80; 95% CI, 0.61-1.06; p = 0.117). Relative to the remaining patients with vitiligo, those with vitiligo and comorbid PD experienced an elevated risk of all-cause mortality (adjusted HR, 2.63; 95% CI, 1.82-3.80; p < 0.001) and higher prevalence of cardiometabolic comorbidities.

Conclusion: Vitiligo is associated with a lower risk of developing PD. The presence of comorbid PD predisposes patients with vitiligo to elevated mortality and cardiometabolic outcomes.

Keywords: Parkinson’s disease; association; case–control study; cohort study; vitiligo.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Lee A, Gilbert RM. Epidemiology of Parkinson disease. Neurol Clin. (2016) 34:955–65. doi: 10.1016/J.NCL.2016.06.012 - DOI - PubMed
    1. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. . Parkinson disease. Nat Rev Dis Primers. (2017) 3:1–21. doi: 10.1038/NRDP.2017.13 - DOI - PubMed
    1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. . Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. (1997) 276:2045–7. doi: 10.1126/SCIENCE.276.5321.2045 - DOI - PubMed
    1. Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. (2018) 57:1157–64. doi: 10.1111/ijd.14055, PMID: - DOI - PubMed
    1. Bergqvist C, Ezzedine K. Vitiligo: a review. Dermatology. (2020) 236:571–92. doi: 10.1159/000506103 - DOI - PubMed

LinkOut - more resources